



Impact of bedside open lung biopsies on the management of mechanically ventilated immunocompromised patients with acute respiratory distress syndrome of unknown etiology

Emmanuel Charbonney MD^{a,*}, John Robert MD^b, Jean-Claude Pache MD^c,
Jean-Claude Chevrolet MD^a, Philippe Eggimann MD^d

^aIntensive Care, Geneva University Hospital, 1211 Geneva, Switzerland

^bThoracic Surgery, Geneva University Hospital, 1211 Geneva, Switzerland

^cClinical Pathology, Geneva University Hospital, 1211 Geneva, Switzerland

^dDepartment of Intensive Care Medicine and Burn Center, CHUV, 1011 Lausanne, Switzerland

Keywords:

Acute respiratory distress syndrome;
Surgical biopsy;
Immunocompromised;
Bedside

Abstract

Background: Open lung biopsy (OLB) is helpful in the management of patients with acute respiratory distress syndrome (ARDS) of unknown etiology. We determine the impact of surgical lung biopsies performed at the bedside on the management of patients with ARDS.

Methods: We reviewed all consecutive cases of patients with ARDS who underwent a surgical OLB at the bedside in a medical intensive care unit between 1993 and 2005.

Results: Biopsies were performed in 19 patients mechanically ventilated for ARDS of unknown etiology despite extensive diagnostic process and empirical therapeutic trials. Among them, 17 (89%) were immunocompromised and 10 patients experienced hematological malignancies. Surgical biopsies were obtained after a median (25%–75%) mechanical ventilation of 5 (2–11) days; mean (\pm SD) PaO₂/FiO₂ ratio was 119.3 (\pm 34.2) mm Hg. Histologic diagnoses were obtained in all cases and were specific in 13 patients (68%), including 9 (47%) not previously suspected. Immediate complications (26%) were local (pneumothorax, minimal bleeding) without general or respiratory consequences. The biopsy resulted in major changes in management in 17 patients (89%). It contributed to a decision to limit care in 12 of 17 patients who died.

Conclusion: Our data confirm that surgical OLB may have an important impact on the management of patients with ARDS of unknown etiology after extensive diagnostic process. The procedure can be performed at the bedside, is safe, and has a high diagnostic yield leading to major changes in management, including withdrawal of vital support, in the majority of patients.

© 2009 Elsevier Inc. All rights reserved.

Abbreviations: ARDS, acute respiratory distress syndrome; BAL, bronchoalveolar lavage; OLB, open lung biopsy.

* Corresponding author. Critical Care Department, St Michael's Hospital, Toronto, Ontario, Canada M5B 1W8.

E-mail addresses: charbonneye@smh.toronto.on.ca (E. Charbonney), john.robert@hcuge.ch (J. Robert), jean-claude.pache@hcuge.ch (J.-C. Pache), jean-claude.chevrolet@hcuge.ch (J.-C. Chevrolet), philippe.eggimann@chuv.ch (P. Eggimann).

1. Introduction

Acute respiratory distress syndrome (ARDS) is a frequent cause of long duration of mechanical ventilation in critically ill patients [1]. Guidelines for the management of this syndrome include the identification of all possible causes susceptible to benefit from a specific treatment [2,3]. Nevertheless, despite an extensive diagnostic process, including sophisticated imaging techniques (high-resolution computed tomodensitometry, nuclear magnetic resonance, positron emission tomography) and microbiology (cultures, serology-based and polymerase chain reaction–based detection of microorganisms in the blood or in specimens obtained through bronchoalveolar lavage [BAL]), the etiology of ARDS remains unknown in 5% to 10% of patients [4,5].

In worsening ARDS of unidentified cause, many clinicians empirically combine broad spectrum antimicrobial agents with immunosuppressive therapy as steroids, and the impact of such potentially contradictory strategies may itself contribute to worsen the prognosis [6,7]. In this situation, lung tissue histologic examination may be useful, particularly in immunocompromised patients as suggested from older series [8,9]. Hence, surgical biopsy is a recognized accurate diagnostic method for diffuse lung disease in immunocompetent patients [10]. In patients with respiratory distress, many authors suggest that surgical open lung biopsies (OLBs) can be performed safely with a high diagnosis yield [11,12], even if they have hematologic diseases [13]. Papazian et al [14] reported in 1998 a very low rate of complications and suggested that such procedure may be performed at the bedside.

We reviewed specifically our local surgical OLBs performed at the bedside of patients with ARDS of unknown etiology after extensive diagnostic process and requiring mechanical ventilation for persistent respiratory failure despite aggressive empirical treatments. The scope was to evaluate whether that procedure had brought an impact on the management or treatment decision in these patients.

2. Patients and methods

We identified retrospectively all patients hospitalized in the medical intensive care unit (ICU) of our institution with ARDS who underwent a bedside surgical OLB between 1993 and 2005. This unit is a tertiary and teaching hospital with 1500 beds, with an average of 1500 admissions every year for a median length of stay of 3 days. The ethical committee of the institution approved the extraction of data from the medical charts. Potential cases were identified through a review of the operative protocols of the thoracic surgery and completed by an electronic search in the database of the Department of Clinical Pathology. Patients with documented ARDS were then included. Acute respiratory distress syndrome was defined as brutal onset event, severe hypoxemia (PO_2/FiO_2 ratio, <200 mm Hg), with

bilateral infiltrates on chest x-ray, and a pulmonary capillary wedge pressure of less than 18 mm Hg, or no evidence of heart failure on echocardiography [15].

2.1. Extraction of the data

Data extracted from the medical records and files were demographic characteristics, reason for admission, underlying diseases, operation report, and histology from lung biopsies. We also extracted characteristics of eventual organ failures, parameters of mechanical ventilation, oxygenation parameters, and catecholamine requirements on the day of surgery for lung biopsy. All diagnostic procedures performed before the biopsy were recorded (cellular characteristics of BAL; imaging documents; complete available microbiological information, including serology). We then look at potential local complications related to surgery (air leak, pneumothorax, and bleeding) and at the impact on the management of the patients after biopsy.

2.2. Surgical procedure and histology analysis

The surgical lung biopsy was carried out at the patient's bedside in the intensive care unit by 2 surgeons. Anesthesia was provided by midazolam or propofol, combined with sulfentanyl, completed by nondepolarizing neuromuscular blocking agents. All patients were mechanically ventilated for their respiratory failure, through an orotracheal low-cuff pressure single-lumen tube. The orotracheal tube used in every patient was not changed, that is, for a selective bronchial intubation device. When pulmonary infiltrates were bilateral and homogeneous, preference was given to a left-sided approach for a resection of the tip of the lingula as described by Miller et al [16].

The axillary-anterior incision, approximately 5 cm long, was carried out under the breast, to gain access to the upper edge of the sixth rib. When present, pleural fluid was collected for bacteriologic and/or cytologic purposes. The 2 adjacent ribs were kept apart with a retractor. The tip of the lingula was then exteriorized and resected with a mechanical GIA-type stapler, the ventilator being disconnected during the stapling. The piece of lung retrieved was sent for extensive microbiological and pathologic examinations, the latter like a frozen section. A single chest tube was introduced into the pleural cavity through the incision itself, and the incision was closed in 3 layers with resorbable material (including the skin). The whole procedure took 30 to 45 minutes, and the chest tube was removed a couple of days later, after having checked for the absence of any air leak and/or excessive fluid output (>150 mL/d). Biopsies were analyzed within 24 to 48 hours from a pathologist with expertise in lung diseases. All cases were discussed in a multidisciplinary meeting that included intensivists, pathologists, surgeons, pneumologists, and infectiologists or onco-hematologists, and additional tests were performed when appropriate.

3. Results

Of 54 patients who underwent a surgical lung biopsy in the institution, 19 open biopsies were performed in the medical ICU at the bedside for ARDS between 1993 and 2005. The 19 patients represented around 8% to 10% of all ARDS and their characteristics at the time of biopsy are summarized in Table 1. As described in Table 2, a majority (89%) of the patients were immunocompromised and many received long-term corticosteroids. Two patients were not immunosuppressed and developed an ARDS after cardiac and plastic surgery, respectively. All patients received broad spectrum antimicrobials for suspected infection.

The diagnostic workup performed before selection for a bedside surgical OLB is listed in Table 3. All but one patient had a bronchoscopic BAL 2 to 5 days before the biopsy, with systematic analysis of cellular content and extensive microbiological workup. Cellular content was nonspecific and microbiological results were negative in all cases. Two polymerase chain reaction procedures performed on material obtained from BAL gave false-positive results (*Pneumocystis jiroveci*, herpes simplex virus), not confirmed by culture and/or the biopsies. All patients had a high-resolution computed tomography of the lung, which revealed nonspecific diffuse interstitial involvement with various degrees of alveolar involvement in all cases.

The biopsy was performed at the lingula in 12 patients (63%), at the right lower lobe in 4 (21%), and in 3 others at the left lower lobe, the right middle lobe, and the right upper lobe, respectively. Other locations than lingula were chosen, either for technical reasons or because of more dense opacity. Histology obtained from biopsies are summarized in Table 4. Biopsies resulted in a histologic diagnosis in all patients. A

specific diagnosis was reached in 13 patients (68%), which was not previously suspected in 9 patients (47%). Nine patients had a diagnosis of diffuse alveolar damage, with evidence of a fibroproliferative stage in 4 of them. An unspecific diagnostic procedure was made in 6 patients (32%). The lingula gave a similar yield of specific diagnosis compared to other sites (66% vs 57%).

An infection was documented in 7 cases: cytomegalovirus in 4, hematogenously spread disseminated *Candida albicans*, and *P jiroveci* pneumonia which was negative on BAL performed 2 days before surgery in each, respectively. A respiratory syncytial virus grew from culture of the biopsy in an additional case initially scored as nonspecific pneumonia compatible with a viral infection. No bacteria grew from culture of the tissue except a small amount of coagulase-negative *Staphylococcus* in 1 case which was interpreted as a contaminant.

3.1. Impact of the biopsies on the treatment of the patients

The impact of the biopsies on the treatment of each patient is listed in Table 4. Biopsies resulted in changes (simple or multiple) in the treatment in 17 patients (89%), as summarized in Table 5. The treatment was not changed in only 2 patients. One patient with histology of diffuse alveolar damage, corresponding to the exsudative phase of a secondary ARDS. The other patient died before the identification of an unexpected *P jiroveci* pneumonia for which a specific treatment could not be given.

3.2. Outcome

Only 2 patients (11%) could be weaned from mechanical ventilation and were discharged alive from the ICU (Table 4). The median of total duration of mechanical ventilation was 11 (5-31) days. Fourteen of the 17 patients who died developed persistent multiple organ failure or unresponsive hypoxemia. The median time (range) between lung biopsies and death was 10 (3-27) days.

However, only 5 died from organ failure that did not respond to maximal treatment. The biopsy resulted in a direct withdrawal of vital support in 3 patients owing to the reported diagnosis (severe lung fibrosis in 2 and carcinomatous lymphangitis in 1) among the context of worsening critical state of the patient. It resulted in a main contribution to the decision to limit the extent of the care in 9 additional patients, and all ultimately died from further withdrawal of vital support.

3.3. Adverse effects of surgery

Local complications developed after surgery in 5 patients (26%). A pneumothorax requiring the insertion of an additional chest tube developed in 2 patients, and surgery

Table 1 Characteristics of the patients at time of the surgical OLB

Characteristics	
Age (y), mean \pm SD	50 \pm 15
Male sex, n (%)	11 (57.9)
Patients under immunosuppressive treatment before the biopsy, n (%)	17 (89.5)
Neutropenic patients, n (%)	7 (36.8)
Empirical broad spectrum antibiotic, n (%)	19 (100)
Antifungal therapy, n (%)	8 (42.1)
Antiviral therapy, n (%)	4 (21.1)
Organ system failure, median (25%-75%)	2 (2-3)
PaO ₂ /Fio ₂ ratio (mm Hg), mean \pm SD	119.3 \pm 34.2
PEEP the day of biopsy (cm H ₂ O), mean \pm SD	6 \pm 3
Duration of mechanical ventilation before the biopsy (d), median (25%-75%)	5 (2-11)
Total duration of mechanical ventilation (d), median (25%-75%)	11(5-31)
Vasopressor requirement before the biopsy, n (%)	14 (73.7)
Surgical open biopsy of the lingula, n (%)	13 (68.4)

PEEP indicates positive-end expiratory pressure.

Table 2 Immunosuppression description^a

Patient (sex [F/M]; age [y])	Main underlying diseases at ICU admission	Immunosuppressive therapy before development of the ARDS
1. (F; 41)	Acute myeloid leukemia, M5 type	Bone marrow transplantation, cyclosporine, neutropenia
2. (M; 54)	Acute myeloid leukemia, M6 type	Bone marrow transplantation, neutropenia
3. (M; 17)	Acute biphenotypic leukemia	Bone marrow transplantation, neutropenia
4. (M; 46)	Clinical suspicion of idiopathic lung fibrosis	High-dose corticosteroids, chronic alcoholism
5. (F; 66)	Goodpasture syndrome	High-dose corticosteroids, cyclophosphamid
6. (M; 58)	Lung transplantation 22 months ago	Tacrolimus, mycophenolate, and corticosteroids
7. (M; 47)	Epidermoid carcinoma of the esophagus	Corticosteroids for late phase of a postoperative ARDS
8. (F; 63)	Liver cirrhosis (hepatitis C) and sarcoidosis	Long-term corticosteroids
9. (M; 22)	Acute myeloid leukemia, M4 type	Bone marrow transplantation, corticosteroids
10. (M; 49)	Hodgkin disease, stage IIA	Induction chemotherapy, neutropenia
11. (M; 52)	Aplastic anemia	Autologous stem cell transplantation, cyclosporine, neutropenia
12. (M; 45)	Clinical suspicion of idiopathic lung fibrosis	High-dose corticosteroids
13. (F; 41)	Chronic myeloid leukemia, granulomatosis	Bone marrow transplantation, cyclosporine, neutropenia
14. (F; 67)	Plastic surgery (after breast cancer)	None
15. (F; 66)	Hodgkin disease, stage IVB	High-dose corticosteroids
16. (M; 69)	Cardiac surgery (valve replacement)	None
17. (F; 73)	Hodgkin disease, stage IVB	Induction chemotherapy, neutropenia, corticosteroids
18. (F; 52)	Paracolic abscess (actinomyces)	Corticosteroids for 2 wks
19. (M; 39)	Acute myeloid leukemia, M2 type	Bone marrow transplantation, tacrolimus, mycophenolate

M indicates male; F, female.

^a For patients 5, 6, 9, 12, 15, and 17, corticosteroids were part of the treatment of the underlying condition. They were empirically started for the current episode of acute respiratory failure in patients 4, 7, and 12.

was necessary for persistent air leak in one of them. A blood loss of more than 200 mL required transfusion in 2 patients of 4 and 3 U of red cells, respectively. These 2 patients also sustained a thrombopenia before the biopsy, and both required additional hematologic support by transfusion of 2 and 4 U of thrombocytes, respectively. No patient required transfusion of fresh frozen plasma.

4. Discussion

Our data confirm that surgical OLB for ARDS of unknown etiology is safe and may provide important information susceptible to induce major changes in the management of these patients. This has already been previously suggested by several series, including in immunocompromised patients in whom empirical treatment of all potential etiologies may be detrimental [11-14,17] and in early-stage ARDS of suspected noninfectious origin [18]. In addition, despite many theoretical advantages and encouraging preliminary reports, transbronchial biopsies may not represent a good alternative to surgical OLB in severely ill ventilated ARDS patients [19-21].

A particular interest of our small retrospective series is that all biopsies have been performed in the ICU at the bedside of mechanically ventilated patients. This allowed us

to avoid moving these patients to the operative room, a procedure known to be associated with potential important morbidity in critically ill patients [22].

The biopsy resulted in major change in the management of 17 (89%) of the 19 patients. This finding is consistent with those of previous reports and emphasizes the usefulness of surgical OLBs in worsening ARDS [11,13,14,23,24]. We observed a very high mortality rate (89%), due to multiple organ disorders of the patients and the severity of their organic damage. However, and more importantly, the fatal issue resulted from a decision to limit the extent of the care directly related to the result of the biopsy in 12 patients, including a rapid withdrawal in 3 of them. Accordingly, the

Table 3 Diagnostic workup before biopsy

Type of investigation	No. of patient (%)
Bronchoscopic BAL	18 (94.7)
Transbronchial biopsy	1 (5.2)
BAL cell content examination	18 (94.7)
Lung fluid ^b and blood microbiology	19 (100)
Fungi and parasites search	19 (100)
PCR ^a for respiratory viruses in BAL	3 (15.8)
Computer tomography	19 (100)

^a Polymerase chain reaction, introduced in 2002.

^b Bronchoalveolar lavage or tracheal aspiration.

Table 4 Histology obtained from surgical OLBs: impact on treatment and final outcome

Patient (sex [F/M]; age [y])	Site of biopsy	Histologic finding of the lung biopsy	Complications of the biopsy	Modifications in treatment according to the results of the biopsy	Outcome, cause of death
1. (F; 41)	Right upper lobe	Pneumonia due to <i>Pneumocystis jiroveci</i>	Pneumothorax	No, dead before results	Death, day 2 right heart failure
2. (M; 54)	Right lower lobe	Diffuse alveolar damage; cytomegalovirus infection	None	Yes, start of gancyclovir and broad spectrum antibiotics stopped	Death, day 4 CNS hemorrhage
3. (M; 17)	Lingula	Cytomegalovirus infection	None	Yes, start of gancyclovir and broad spectrum antibiotics stopped	Death, day 24 ^a multiple organ failure
4. (M; 46)	Lingula	Diffuse carcinomatous lymphangitis	None	Yes, withdrawal of vital support	Death, day 2 refractory hypoxemia
5. (F; 66)	Lingula	Cytomegalovirus infection	Hemorrhage	Yes, start of gancyclovir and high-dose corticosteroids stopped	Death, day 2 ^a multiple organ failure
6. (M; 58)	Right middle lobe	Acute rejection grade A3 (bronchiolitis obliterans)	None	Yes, start of high dose of corticosteroids and of cyclosporine	Survival, discharged on day 10
7. (M; 47)	Lingula	Hematogenous abscesses (<i>Candida albicans</i>)	None	Yes, start of amphotericine B and corticosteroids stopped	Survival, discharged on day 28
8. (F; 63)	Lingula	Diffuse alveolar damage in fibroproliferative phase	Hemorrhage	Yes, increase of corticosteroids and broad spectrum antibiotics stopped	Death, day 10 ^a multiple organ failure
9. (M; 22)	Lingula	Histologic damage related to busulfan toxicity	None	Yes, increase of corticosteroids and broad spectrum antibiotics stopped	Death, day 10 ^a refractory hypoxemia
10. (M; 49)	Lingula	Diffuse alveolar damage; in exsudative phase	None	Yes, broad spectrum antibiotics stopped	Death, day 46 ^a multiple organ failure
11. (M; 52)	Right lower lobe	Diffuse alveolar damage; in fibroproliferative phase	None	Yes, increase of corticosteroids and broad spectrum antibiotics stopped	Death, day 33 ^a multiple organ failure
12. (M; 45)	Lingula	Diffuse alveolar damage; in fibroproliferative phase	None	Yes, adaptation of corticosteroids and broad spectrum antibiotics stopped	Death, day 34 refractory hypoxemia
13. (F; 41)	Right lower lobe	Diffuse alveolar damage; in exsudative phase; TE	None	Yes, start of defibrotid (Prociclide, Crinos SpA, Milan, Italy) ^b and broad spectrum antibiotics stopped	Death, day 33 cardiac arrest
14. (F; 67)	Lingula	Histologic pneumonia with viral inclusions	None	Yes start of ribavarin	Death, day 33 ^a refractory hypoxemia
15. (F; 66)	Lingula	Lung fibrosis related to toxicity of bleomycine	None	Yes, withdrawal of vital support	Death, day 3 refractory hypoxemia
16. (M; 69)	Left lower lobe	Diffuse alveolar damage; in exsudative phase	None	No	Death, day 1 multiple organ failure
17. (F; 73)	Lingula	Lung fibrosis related to toxicity of bleomycine	Pneumothorax	Yes, adaptation of corticosteroids and broad spectrum antibiotics stopped	Death, day 7 ^a multiple organ failure
18. (F; 52)	Right lower lobe	Diffuse alveolar damage; cytomegalovirus infection	Surgical air leakage	Yes, start of gancyclovir and corticosteroids stopped	Death, day 36 ^a refractory hypoxemia
19. (M; 39)	Lingula	Diffuse alveolar damage; in fibroproliferative phase	None	Yes, withdrawal of vital support	Death, day 8 refractory hypoxemia

CNS indicates central nervous system; TE, thromboembolia.

^a Limitation of the extent of the care, ultimately contributing to withdrawal of vital support.

^b For liver veno-occlusive disease.

Table 5 Changes in treatment

Changes	No. of patient (%)
New anti-infectious therapy	5 (26.3)
New immunosuppressive therapy	3 (15.8)
Unnecessary antibiotics stopped	8 (42.1)
Corticosteroids stopped	3 (15.8)
Change of corticosteroids dosage	4 (21.1)
Withdrawal of supportive therapy	3 (15.8)

biopsy allowed to avoid further futile care in 12 (71%) of 17 patients who ultimately died as a consequence of their ARDS and multiple organ failure.

The 19 patients of the present series were relatively homogenous. All sustained severe forms of ARDS. Extensive diagnostic workup was negative in all of them, and biopsy was only decided after trials of empirical treatments, including broad spectrum antimicrobials and steroids for those suspected to be in the fibroproliferative phase of ARDS [25].

Despite the severity of the ARDS, the procedure was safe. Respiratory failure did not worsen owing to the surgical biopsy. We observed only 5 local complications (26%), and new surgery for persistent air leakage was required in only 1 patient. These findings are comparable with those of the literature which reported occurrences in 15% to 25% of cases [26,27]. It is possible that pneumothorax might be avoided by using 2 chest tubes instead of 1. No patient died as a consequence of surgery, and no change in vasopressor use or immediate oxygenation need was observed. Early death observed in patients 1 and 16 could have been related to the procedure, but no change in intrathoracic pressures or mechanical ventilation was noticed.

Several limitations may limit the extent of the information we can draw from our data. Our small series is not representative of the population sustaining ARDS, but only of a particular subgroup in a majority of immunocompromised patients carefully selected by a multidisciplinary team after negative extended diagnostic assessment and empirical treatments. In contrast to other series [11,14], all our patients were treated with broad spectrum antibiotics at the time of microbiological sampling by BAL, which may have resulted in a lower sensitivity of these examinations. However, none of our patients responded to empirical treatments and, except one hematogenous disseminated candidiasis, the biopsies did show unsuspected infection in 6 patients.

5. Conclusion

Surgical OLBs may be safely performed at the bedside of mechanically ventilated patients with ARDS of unknown etiology after extensive diagnostic process and despite empirical therapeutic trials, particularly if they are immunocompromised. The procedure is associated with a high

diagnostic yield leading to specific modifications of the management of the patients, including withdrawal and limitation of futile care in a majority of them.

References

- [1] McIntyre RC, Pulido EJ, Bensard DD, et al. Thirty years of clinical trials in acute respiratory distress syndrome. *Crit Care Med* 2000;28:3314-31.
- [2] Marini JJ, Gattinoni L. Ventilatory management of acute respiratory distress syndrome: a consensus of two. *Crit Care Med* 2004;32:250-5.
- [3] Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. *Intensive Care Med* 2004;30:536-55.
- [4] Ware LB, Matthay MA. The acute respiratory distress syndrome. *N Engl J Med* 2000;342:1334-49.
- [5] Marquette CH, Copin MC, Wallet F, et al. Diagnostic tests for pneumonia in ventilated patients: prospective evaluation of diagnostic accuracy using histology as a diagnostic gold standard. *Am J Respir Crit Care Med* 1995;151:1878-88.
- [6] Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. *N Engl J Med* 2006;354:1671-84.
- [7] Adhikari N, Burns KE, Meade MO. Pharmacologic therapies for adults with acute lung injury and acute respiratory distress syndrome. *Cochrane Database Syst Rev* 2004;CD004477.
- [8] Greenman RL, Goodall PT, King D. Lung biopsy in immunocompromised hosts. *Am J Med* 1975;59:488-96.
- [9] McKenna Jr RJ, Mountain CF, McMurtrey MJ. Open lung biopsy in immunocompromised patients. *Chest* 1984;86:671-4.
- [10] Shah SS, Tsang V, Goldstraw P. Open lung biopsy: a safe, reliable and accurate method for diagnosis in diffuse lung disease. *Respiration* 1992;59:243-6.
- [11] Patel SR, Karpaliotis D, Ayas NT, et al. The role of open-lung biopsy in ARDS. *Chest* 2004;125:197-202.
- [12] Flabouris A, Myburgh J. The utility of open lung biopsy in patients requiring mechanical ventilation. *Chest* 1999;115:811-7.
- [13] Zihlif M, Khanchandani G, Ahmed HP, et al. Surgical lung biopsy in patients with hematological malignancy or hematopoietic stem cell transplantation and unexplained pulmonary infiltrates: improved outcome with specific diagnosis. *Am J Hematol* 2005;78:94-9.
- [14] Papazian L, Thomas P, Bregcon F, et al. Open-lung biopsy in patients with acute respiratory distress syndrome. *Anesthesiology* 1998;88:935-44.
- [15] Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med* 1994;149:818-24.
- [16] Miller RR, Nelems B, Muller NL, et al. Lingular and right middle lobe biopsy in the assessment of diffuse lung disease. *Ann Thorac Surg* 1987;44:269-73.
- [17] White DA, Wong PW, Downey R. The utility of open lung biopsy in patients with hematologic malignancies. *Am J Respir Crit Care Med* 2000;161:723-9.
- [18] Kao KC, Tsai YH, Wu YK, et al. Open lung biopsy in early-stage acute respiratory distress syndrome. *Crit Care* 2006;10:R106.
- [19] Burt ME, Flye MW, Webber BL, et al. Prospective evaluation of aspiration needle, cutting needle, transbronchial, and open lung biopsy in patients with pulmonary infiltrates. *Ann Thorac Surg* 1981;32:146-53.
- [20] Rao VK, Ritter J, Kollef MH. Utility of transbronchial biopsy in patients with acute respiratory failure: a postmortem study. *Chest* 1998;114:549-55.

- [21] Bulpa PA, Dive AM, Mertens L, et al. Combined bronchoalveolar lavage and transbronchial lung biopsy: safety and yield in ventilated patients. *Eur Respir J* 2003;21:489-94.
- [22] Waydhas C. Intrahospital transport of critically ill patients. *Crit Care* 1999;3:R83-9.
- [23] Lachapelle KJ, Morin JE. Benefit of open lung biopsy in patients with respiratory failure. *Can J Surg* 1995;38:316-21.
- [24] Papazian L, Doddoli C, Chetaille B, et al. A contributive result of open-lung biopsy improves survival in acute respiratory distress syndrome patients. *Crit Care Med* 2007;35:755-62.
- [25] Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 1998; 280:159-65.
- [26] Hunninghake GW, Zimmerman MB, Schwartz DA, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2001;164:193-6.
- [27] Lettieri CJ, Veerappan GR, Helman DL, et al. Outcomes and safety of surgical lung biopsy for interstitial lung disease. *Chest* 2005;127: 1600-5.